Conditions: Liver Carcinoma
Keywords: liver transplant hepatocellular carcinoma sirolimus
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 70
Healthy volunteers: no

Brief summary:
This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.

Detailed description:
A total of 70 patients with HCC (mean age: 54.6 years, female/male: 12/58) received a liver transplant and were included in the study. Immunosuppression included de novo sirolimus, low-dose calcineurin inhibitor for 6 to 12 months, with short-course (3 months) or no steroids.

Arms:
arm 1: Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l

Interventions: intervention 1: Sirolimus
Intervention descriptions: intervention 1: Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l

Protocol document: